Forbius, a clinical-stage company that develops biologics for the treatment of fibrosis and cancer, announced today that the first patient has been dosed in a diffuse cutaneous systemic sclerosis (SSc) Phase 1b trial with AVID200, a rationally designed and highly potent inhibitor of TGF-beta 1 & 3.
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been granted de novo classification by the U.S. Food and Drug Administration (FDA) for the Early Bird Bleed Monitoring System.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
LivaNova PLC, a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs).
LivaNova PLC, a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval®sutureless aortic heart valve to treat aortic valve disease. By adding Perceval into Japan’s health insurance system, physicians and patients have greater access to this versatile biological
Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company was the featured innovation success at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University.
LivaNova PLC, a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for Treatment-Resistant Depression (TRD).
Forbius, a clinical-stage company that develops biologics for the treatment of cancer and fibrosis, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai and the Myeloproliferative Neoplasm Research Consortium (MPN-RC).